Dr. Peter Voorhees discusses groundbreaking AQUILA study results, highlighting daratumumab's significant impact on high-risk ...
FDA approves daratumumab for high-risk smoldering multiple myeloma, transforming treatment strategies and enhancing patient outcomes in early intervention.
The CEPHEUS trial is a trial for newly diagnosed multiple myeloma patients who are not eligible for stem cell transplantation, or in whom a transplant was deferred. And 395 patients were randomized ...
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Daratumumab (Darzalex), the first monoclonal antibody approved ...
BEERSE, Belgium--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the European Commission (EC) has granted marketing authorisation for the expanded use of ...
Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for ...
Please provide your email address to receive an email when new articles are posted on . Daratumumab delayed progression of smoldering multiple myeloma compared with active monitoring. Among those who ...
Although daratumumab reduced the risk of disease progression and death for patients with multiple myeloma, the drug was associated with a higher rate of neutropenia. Although daratumumab reduced the ...
Intravenous drip Use of the drug resulted in remission of severe pulmonary and cutaneous ANCA-associated vasculitis that resisted intensive conventional treatment. Daratumumab, a monoclonal antibody, ...
Primary effusion lymphoma is a rare type of non-Hodgkin’s lymphoma that is associated with human immunodeficiency virus (HIV) and human herpesvirus 8 (HHV-8) infections. 1 It typically manifests with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback